-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
People Watch the News Broadcast | “Nanobullets” Turn Viruses into Targets
Category:
发布时间：2023-11-04
【概要描述】
Have you heard of “nano-bullets”? They are drug particles developed using nanotechnology, capable of precisely targeting and effectively eliminating bacteria and viruses.
Have you heard of “nano-bullets”? They are drug particles developed using nanotechnology, capable of precisely targeting and effectively neutralizing bacteria and viruses.
Recently, Li Lei, head of the Formulation Research and Development Center at Shijiazhuang Sihua Pharmaceutical, has been working around the clock to develop “nanobullets.” Not long ago, his team successfully developed a new drug for treating liver fibrosis; however, they encountered a significant challenge: the drug exhibits very low solubility. This means that the human body absorbs it poorly, making it difficult for the drug to exert its intended therapeutic effect.
To overcome this challenging problem, Li Lei and his team tried dozens of formulation methods. Ultimately, they adopted nanotechnology to crush the drug into nanoparticles using a specialized device, achieving a breakthrough. Typically, drug particles can be as small as 10 micrometers, whereas these nano-sized particles average only 100 nanometers. Since 1 micrometer equals 1,000 nanometers, comparing the two is like comparing a soccer ball to a locomotive.
Simply reducing the size of the drug particles is not enough; they tend to clump together, resulting in poor dispersibility. To address this, researchers developed a special coating material that encapsulates the drug particles. This coating not only prevents agglomeration but also enhances the particles’ ability to specifically adhere to the surfaces of target bacteria and viruses. These pathogens act as the coating’s “targets”—once encountered, the particles swiftly home in, penetrate biological barriers, and deliver precise eradication.
Isn’t it remarkable? That’s why this new drug has been designated as a Class 1 National Drug. What exactly is a Class 1 drug? It refers to an original, innovative medication that has never been developed anywhere in the world—neither domestically nor internationally. Although the research and development of such drugs require substantial investment, pose significant technical challenges, and span a lengthy development cycle, thanks to the province’s policy support for strategic emerging industries, Shijiazhuang No. 4 Pharmaceutical is simultaneously pursuing the R&D of five Class 1 drugs.
In fact, many pharmaceutical companies in our province are stepping up their efforts to develop innovative and rare-disease drugs. According to a report by Hebei News Broadcast, in the first three quarters of this year, the value added of strategic emerging industries among large-scale industrial enterprises across the province increased by 6.6% year on year, and even more positive news is yet to come.
Reposted from: Great Wall New Media’s Jiyun Client
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091